BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 25818847)

  • 1. New-onset paresthesias in inflammatory bowel disease.
    Simonetto DA; Papadakis KA
    Gastroenterology; 2015 May; 148(5):906-7. PubMed ID: 25818847
    [No Abstract]   [Full Text] [Related]  

  • 2. Sarcoidosis during infliximab therapy for Crohn's disease.
    Takahashi H; Kaneta K; Honma M; Ishida-Yamamoto A; Ashida T; Kohgo Y; Ohsaki Y; Iizuka H
    J Dermatol; 2010 May; 37(5):471-4. PubMed ID: 20536653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adalimumab-induced lupus erythematosus in Crohn's disease patients previously treated with infliximab.
    Mañosa M; Domènech E; Marín L; Olivé A; Zabana Y; Cabré E; Gassull MA
    Gut; 2008 Apr; 57(4):559; author reply 559-60. PubMed ID: 18334664
    [No Abstract]   [Full Text] [Related]  

  • 4. Adalimumab-induced interstitial pneumonia in a patient with Crohn's disease.
    Casanova MJ; Chaparro M; Valenzuela C; Cisneros C; Gisbert JP
    World J Gastroenterol; 2015 Feb; 21(7):2260-2. PubMed ID: 25717268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucosal expression of basic fibroblastic growth factor, syndecan 1 and tumour necrosis factor-α in Crohn's disease in deep remission under treatment with anti-TNFα antibodies.
    Tursi A; Elisei W; Principi M; Inchingolo CD; Nenna R; Picchio M; Giorgio F; Ierardi E; Brandimarte G
    J Gastrointestin Liver Dis; 2014 Sep; 23(3):261-5. PubMed ID: 25267953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surgery for Crohn's disease and anti-TNF agents: the changing scenario.
    Sorrentino D; Fogel S; Van den Bogaerde J
    Expert Rev Gastroenterol Hepatol; 2013 Nov; 7(8):689-700. PubMed ID: 24161133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Certolizumab (Cimzia) for Crohn's disease.
    Med Lett Drugs Ther; 2008 Oct; 50(1297):81-2. PubMed ID: 18927521
    [No Abstract]   [Full Text] [Related]  

  • 8. Mucosal healing in pediatric Crohn's disease after anti-TNF therapy: a long-term experience at a single center.
    Nobile S; Gionchetti P; Rizzello F; Calabrese C; Campieri M
    Eur J Gastroenterol Hepatol; 2014 Apr; 26(4):458-65. PubMed ID: 24445727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.
    Sands BE; Feagan BG; Rutgeerts P; Colombel JF; Sandborn WJ; Sy R; D'Haens G; Ben-Horin S; Xu J; Rosario M; Fox I; Parikh A; Milch C; Hanauer S
    Gastroenterology; 2014 Sep; 147(3):618-627.e3. PubMed ID: 24859203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [When can TNF-alpha inhibitors against inflammatory bowel disease be withdrawn?].
    Moum B
    Tidsskr Nor Laegeforen; 2007 Jun; 127(12):1673. PubMed ID: 17571118
    [No Abstract]   [Full Text] [Related]  

  • 11. Acute paraplegia after the initiation of anti-tumour necrosis factor-alpha therapy for Crohn's disease.
    Vadikolias K; Kouklakis G; Heliopoulos I; Argyropoulou P; Papanas N; Tzilonidou M; Prassopoulos P; Piperidou H
    Eur J Gastroenterol Hepatol; 2007 Feb; 19(2):159-62. PubMed ID: 17273002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Timing infliximab therapy in pediatric Crohn's disease.
    Kirschner BS; Huo D
    Gastroenterology; 2007 Mar; 132(3):1167-70. PubMed ID: 17383435
    [No Abstract]   [Full Text] [Related]  

  • 13. Education and imaging. Gastrointestinal: Improvement of granuloma annulare with anti-tumour necrosis factor alpha therapy for Crohn's disease.
    Fanning SB; Chapman G; Yau Y; Leong RW
    J Gastroenterol Hepatol; 2010 Jan; 25(1):215. PubMed ID: 20136975
    [No Abstract]   [Full Text] [Related]  

  • 14. Peripheral neuropathy with infliximab therapy in inflammatory bowel disease.
    Burger DC; Florin TH
    Inflamm Bowel Dis; 2009 Dec; 15(12):1772. PubMed ID: 19170193
    [No Abstract]   [Full Text] [Related]  

  • 15. [Biologicals first-line in chronic inflammatory bowel disease? No].
    Herrlinger K; Stange EF
    Dtsch Med Wochenschr; 2011 Sep; 136(36):1789. PubMed ID: 21882135
    [No Abstract]   [Full Text] [Related]  

  • 16. Preventing TB in patients with Crohn's disease needing infliximab or other anti-TNF therapy.
    Rampton DS
    Gut; 2005 Oct; 54(10):1360-2. PubMed ID: 16113045
    [No Abstract]   [Full Text] [Related]  

  • 17. Disseminated tuberculosis in a Crohn's disease patient on anti-TNF alpha therapy despite chemoprophylaxis.
    Bourikas LA; Kourbeti IS; Koutsopoulos AV; Koutroubakis IE
    Gut; 2008 Mar; 57(3):425; author reply 425-6. PubMed ID: 18268059
    [No Abstract]   [Full Text] [Related]  

  • 18. Tuberculosis and treatment with infliximab.
    Zhang Z; Correa H; Bégué RE
    N Engl J Med; 2002 Feb; 346(8):623-6. PubMed ID: 11859880
    [No Abstract]   [Full Text] [Related]  

  • 19. Functional Brain Imaging Reveals Rapid Blockade of Abdominal Pain Response Upon Anti-TNF Therapy in Crohn's Disease.
    Hess A; Roesch J; Saake M; Sergeeva M; Hirschmann S; Neumann H; Dörfler A; Neurath MF; Atreya R
    Gastroenterology; 2015 Oct; 149(4):864-6. PubMed ID: 26264347
    [No Abstract]   [Full Text] [Related]  

  • 20. [Biologicals in gastroenterology: TNF-blockers].
    Scharl M; Rogler G
    Dtsch Med Wochenschr; 2010 Nov; 135(45):2243-52. PubMed ID: 21046532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.